Approval · Notice of Compliance 33390 · 2024
SUBOXONE: Notice of Compliance 33390
Issued June 3, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33390
- Date
- June 3, 2024
- Company
- Indivior Uk LimitedHull, --, United Kingdom
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of serialization information on SUBOXONE film cartons in alignment with GS1 Canada's Pharmacy Board requirements for the implementation of GS1 Data Matrix Barcodes.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SUBOXONE | Not yet assigned | — |
Medicinal ingredients
- BUPRENORPHINE HYDROCHLORIDE 2 MG per STRIP
- NALOXONE HYDROCHLORIDE 0.5 MG per STRIP
- BUPRENORPHINE HYDROCHLORIDE 4 MG per STRIP
- NALOXONE HYDROCHLORIDE 1 MG per STRIP
- BUPRENORPHINE HYDROCHLORIDE 8 MG per STRIP
- NALOXONE HYDROCHLORIDE 2 MG per STRIP
- BUPRENORPHINE HYDROCHLORIDE 12 MG per STRIP
- NALOXONE HYDROCHLORIDE 3 MG per STRIP